Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - purified antigen fractions of inactivated split virions - a/indonesia/05/2005 (h5n1)/pr8-ibcdc-rg2 - injection, emulsion - 3.75 µg haemagglutinin/0.25 ml - purified antigen fractions of inactivated split virions - a/indonesia/05/2005 (h5n1)/pr8-ibcdc-rg2 3.75 µg haemagglutinin/0.25 ml

Singapore - English - HSA (Health Sciences Authority)

seqirus pte. ltd. - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain; influenza virus (sh) b/brisbane/60/2008 - like strain - injection - 15 mcg ha/0.5ml - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain 15 mcg ha/0.5ml; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain 15 mcg ha/0.5ml; influenza virus (sh) b/brisbane/60/2008 - like strain 15 mcg ha/0.5ml

Singapore - English - HSA (Health Sciences Authority)

seqirus pte. ltd. - influenza virus surface antigens (haemagglutinin and neuraminidase) a/turkey/turkey/1/05 (h5n1)-like strain used (nibrg-23) - injection, suspension - > or = 7.5 ug ha - influenza virus surface antigens (haemagglutinin and neuraminidase) a/turkey/turkey/1/05 (h5n1)-like strain used (nibrg-23) 7.5 ug ha/0.5 ml

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human, immunization, disease outbreaks - vaccines, - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.,

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - fluarix tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - suspension for injection - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.

Israel - English - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - a/california/7/2009 (h1n1) pdm09-like strain used nib-74xp derived from a/christchurch/16/2010, a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b), b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15/15/15mc microgram - influenza vaccines